This week, Colorado Governor Jared Polis, D, signed the nation’s first bill that will cap insulin co-pays at $100 per month for people with health insurance.
This week, Colorado Governor Jared Polis, D, signed the nation’s first bill that will cap insulin co-pays at $100 per month for people with health insurance. The bill also authorizes the state’s attorney general (AG) to investigate the rising price of insulin.
The bill was sponsored by State Representative Dylan Roberts, D, whose brother died at 22 of type 1 diabetes complications in August 2016.
The cap will go into effect on January 1, 2020. Insurance companies will pay anything above $100, regardless of how much insulin is used.
The attorney general may begin investigating insulin prices immediately. The law also instructs the attorney general to make recommendations to the state legislature.
In an email to The Center for Biosimilars®, Roberts said the law applies only to those with private insurance.
“For those without insurance, that is still a huge problem that I will continue to work on. I also sponsored 2 successful bills this year to increase access to health insurance,” he said, referring to a bill that creates a public insurance option and another that allows the creation of health insurance cooperatives. The majority of Coloradans are insured, but 4% are not, he said.
“The second part of the insulin bill that was signed into law directs the attorney general to investigate pricing and make recommendations on what we should do next to get at the underlying problem of insulin prices, so I am looking forward to continue working on this issue with the AG and others,” he said.
In a statement, the American Diabetes Association said more than 400,000 people in the state have diabetes. “With the prices of insulin nearly tripling between 2002 and 2013, people with diabetes often face financial hardships affording their insulin,” said LaShawn McIver, MD, a senior vice president.
The ADA and others have been testifying at numerous hearings in Congress over the past few months about the rising cost of insulin.
In response, companies have started their own programs to cut insulin prices or limit co-pays, including Cigna and its pharmacy benefits manager Express Scripts; Eli Lilly, meanwhile, launched its lower-cost insulin lispro injection this week.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.